Overview
- The study, published on Tuesday, November 17, 2026, reports that researchers at CSIR‑CCMB screened small molecules and found compounds that keep Candida albicans in its harmless rounded form rather than letting it form invasive filaments.
- The team traced the effect to glycolysis and highlighted pyruvate kinase as a key metabolic node that controls the shape change that enables tissue invasion.
- One lead compound reduced biofilm formation in lab tests, increased the potency of fluconazole and amphotericin B against the fungus, and materially improved survival in a mouse model of systemic Candida infection.
- The work establishes a preclinical proof of concept for an anti‑virulence approach that disarms disease-causing behavior rather than killing fungal cells, but the compounds remain research candidates needing toxicology, pharmacology and safety studies before clinical development.
- The findings respond to a narrow antifungal pipeline and rising resistance by proposing a strategy that could complement existing drugs and may lower selective pressure for resistance if safety and efficacy are confirmed.